Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

CASI Pharmaceuticals (CASI) Operating Expenses (2022 - 2025)

Historic Operating Expenses for Pharmaceuticals (CASI) over the last 4 years, with Q2 2025 value amounting to -$13.2 million.

  • Pharmaceuticals' Operating Expenses fell 2143.52% to -$13.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$38.0 million, marking a year-over-year increase of 5979.56%. This contributed to the annual value of -$50.8 million for FY2024, which is 1248.56% down from last year.
  • According to the latest figures from Q2 2025, Pharmaceuticals' Operating Expenses is -$13.2 million, which was down 2143.52% from -$14.0 million recorded in Q1 2025.
  • In the past 5 years, Pharmaceuticals' Operating Expenses ranged from a high of $15.2 million in Q2 2023 and a low of -$96.7 million during Q4 2022
  • Its 4-year average for Operating Expenses is -$13.0 million, with a median of -$285500.0 in 2023.
  • Per our database at Business Quant, Pharmaceuticals' Operating Expenses skyrocketed by 3298.58% in 2023 and then crashed by 19243.15% in 2024.
  • Pharmaceuticals' Operating Expenses (Quarter) stood at -$96.7 million in 2022, then rose by 14.37% to -$82.8 million in 2023, then surged by 86.89% to -$10.9 million in 2024, then fell by 21.44% to -$13.2 million in 2025.
  • Its Operating Expenses stands at -$13.2 million for Q2 2025, versus -$14.0 million for Q1 2025 and -$10.9 million for Q2 2024.